News for Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Summary Ionis Pharmaceuticals Inc (IONS) has announced positive topline results from its Essence study, evaluating olezarsen in patients with moderate hypertrig

[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hy

Ionis Pharmaceuticals (IONS) has released promising topline results from the Essence study, which assessed the efficacy of olezarsen in individuals with moderat

Ionis Pharmaceuticals (IONS) reports positive topline results from the Essence study on olezarsen targeting hypertriglyceridemia. Both 80 mg and 50 mg d

Analyzing the Impact of Tweedy Browne (Trades, Portfolio)'s Latest 13F Filing Tweedy Browne (Trades, Portfolio) recently submitted the 13F filing for the first

We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general c

Ionis Pharmaceuticals, Inc. (IONS) to hold its 2025 virtual Annual Meeting of Stockholders on June 5, followed by a corporate update. Stockholders must

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. ( PRAX), a clinical-stage biopharmaceutical company translating genetic insights int

**media[612782]**

In a recent update, analyst Debjit Chattopadhyay from Guggenheim has adjusted the price target for Ionis Pharmaceuticals (IONS). The price target has been lower

On May 1, 2025, HC Wainwright & Co. analyst Mitchell Kapoor maintained a "Buy" rating on Ionis Pharmaceuticals (IONS) while raising the price target from $45.00

Guggenheim has revised its price target for Ionis Pharmaceuticals (IONS), decreasing it slightly from $65 to $64 while maintaining a Buy rating on the stock. Th

Revenue: $132 million in Q1 2025, a 10% increase year-over-year.TRYNGOLZA Sales: Over $6 million in net product sales in its first full quarter on the market.S

Apr 30, 2025 / 03:30PM GMTOperator Good morning, and welcome to the Ionis first quarter 2025 financial results conference call. As a reminder, this call is bein

Key Highlights: Ionis Pharmaceuticals (IONS) exceeds first-quarter expectations with TRYNGOLZA's successful launch. Analysts predict an average price tar

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ETCompany ParticipantsWade Walke - SVP, IRBrett Monia -...

Oil prices to fall through 2026 on supply glut – GS. Sony increases costs of PS5 in Europe, Australia, and New Zealand amid tariff risks. Tech stocks rebound on Trump tariff exemptions.